Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ampicillin Sodium

FDA-approved product (injectable, injection), marketed as Ampicillin Sodium, Omnipen-N, Penbritin-S and 13 more.

Registered studies
50+
Lab records
69
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ampicillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial meningitis
  • Endocarditis
  • Eye infection
  • Gonorrhea
  • Infection
  • Infectious meningitis
  • Sepsis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Penicillins with extended spectrum; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CA01; WHO ATC J01CA51; WHO ATC S01AA19

Repurposing investigation

Ampicillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 5 of 20 lab records
  • E. coli: measured active in 4 of 10 lab records
  • K. pneumoniae: measured active in 12 of 39 lab records
Open Ampicillin Sodium in ChEMBL Registered studies below
Show the 69 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ampicillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extended Azithromycin Treatment in Prelabor Rupture of Membranes

    NCT07669207 · start 2026-08-19

    Registered record
    Registry ID
    NCT07669207
    Conditions
    Preterm Prelabor Rupture of Membranes; PPROM
    Interventions
    Azithromycin (Azithro); Standard Azithromycin Dosing
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-08-19
    Completion
    2028-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Prelabor Rupture of Membranes; PPROM
    InterventionAzithromycin (Azithro); Standard Azithromycin Dosing
    PhasePhase 4
    Registry statusRecruiting

  • Aminoglycosides in Early Sepsis

    NCT06712641 · start 2026-04-23

    Registered record
    Registry ID
    NCT06712641
    Conditions
    Sepsis
    Interventions
    Gentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-23
    Completion
    2033-05
    Enrolment
    1,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionGentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    PhasePhase 4
    Registry statusRecruiting

  • Antibiotic Prophylaxis Versus Placebo in Alveolar Bone Grafting: A Randomized Controlled Trial

    NCT07296302 · start 2026-02

    Registered record
    Registry ID
    NCT07296302
    Conditions
    Alveolar Ridge Augmentation; Bone Grafting; Antibiotic Prophylaxis
    Interventions
    Amoxicillin 500 mg (prophylactic regimen); Placebo Capsule (matched dosing schedule)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2027-08
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlveolar Ridge Augmentation; Bone Grafting; Antibiotic Prophylaxis
    InterventionAmoxicillin 500 mg (prophylactic regimen); Placebo Capsule (matched dosing schedule)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication

    NCT07115173 · start 2025-12-01

    Registered record
    Registry ID
    NCT07115173
    Conditions
    Helicobacter Infection
    Interventions
    This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2027-12-31
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Infection
    InterventionThis study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
    PhasePhase 4
    Registry statusNot yet recruiting

  • Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

    NCT05870683 · start 2023-05-24

    Registered record
    Registry ID
    NCT05870683
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tegoprazan; Amoxicillin; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-05-24
    Completion
    2023-12-30
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTegoprazan; Amoxicillin; Esomeprazole
    PhaseNot applicable
    Registry statusUnknown

  • The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation

    NCT04552080 · start 2022-12-29

    Registered record
    Registry ID
    NCT04552080
    Conditions
    Patients Undergoing Oral Implant Therapy
    Interventions
    Amoxicillin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-12-29
    Completion
    2026-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Undergoing Oral Implant Therapy
    InterventionAmoxicillin; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

    NCT05302531 · start 2022-12-09

    Registered record
    Registry ID
    NCT05302531
    Conditions
    Short Bowel Syndrome; Infection, Bacterial
    Interventions
    Amoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole trimethoprim
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-12-09
    Completion
    2025-02
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShort Bowel Syndrome; Infection, Bacterial
    InterventionAmoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole trimethoprim
    PhasePhase 1
    Registry statusUnknown

  • One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL

    NCT05728424 · start 2022-09-20

    Registered record
    Registry ID
    NCT05728424
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan, Amoxicillin, Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-09-20
    Completion
    2023-05-01
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan, Amoxicillin, Levofloxacin
    PhasePhase 3
    Registry statusUnknown

  • Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication

    NCT05469685 · start 2022-08-01

    Registered record
    Registry ID
    NCT05469685
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan; Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2023-09-30
    Enrolment
    914

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan; Amoxicillin
    PhasePhase 4
    Registry statusCompleted

  • Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

    NCT05432115 · start 2022-06-25

    Registered record
    Registry ID
    NCT05432115
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tetracyclin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-06-25
    Completion
    2023-10
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTetracyclin
    PhasePhase 4
    Registry statusUnknown

  • Collaborative Urological Prosthetics Investigation Directive Research Group

    NCT05100654 · start 2022-04-22

    Registered record
    Registry ID
    NCT05100654
    Conditions
    Erectile Dysfunction; Penile Prosthesis Infection
    Interventions
    Doxycycline; Ciprofloxacin; Augmentin; Bactrim
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2022-04-22
    Completion
    2028-01-01
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Penile Prosthesis Infection
    InterventionDoxycycline; Ciprofloxacin; Augmentin; Bactrim
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

    NCT04901117 · start 2021-06

    Registered record
    Registry ID
    NCT04901117
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06
    Completion
    2023-08
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 more
    PhasePhase 4
    Registry statusUnknown

  • RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

    NCT04514653 · start 2020-08-25

    Registered record
    Registry ID
    NCT04514653
    Conditions
    Neovascular Age-Related Macular Degeneration (nAMD)
    Interventions
    Ranibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3; Local Steroid; Topical Steroid; ABBV-RGX-314 Dose 4
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-08-25
    Completion
    2027-02
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeovascular Age-Related Macular Degeneration (nAMD)
    InterventionRanibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3 +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

    NCT04879030 · start 2020-01-01

    Registered record
    Registry ID
    NCT04879030
    Conditions
    COPD Exacerbation Acute
    Interventions
    Beta-Lactams; Fluoroquinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2020-12-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD Exacerbation Acute
    InterventionBeta-Lactams; Fluoroquinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia

    NCT04041791 · start 2019-08-19

    Registered record
    Registry ID
    NCT04041791
    Conditions
    Pneumonia
    Interventions
    Benzyl penicillin; Gentamicin Sulfate; Ceftriaxone; Amoxicillin Clavulanate; Intravenous fluid; Nasogastric feeds; Ampicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-19
    Completion
    2024-04-05
    Enrolment
    4,392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionBenzyl penicillin; Gentamicin Sulfate; Ceftriaxone; Amoxicillin Clavulanate +3 more
    PhasePhase 3
    Registry statusCompleted